- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01604291
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients
연구 개요
상태
정황
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Afula, 이스라엘, 18101
- Haemek Hospital; Gastroenterology
-
Ashkelon, 이스라엘, 78278
- Barzilai MC; Gastroenterology
-
Beer Sheva, 이스라엘, 84105
- Soroka Medical Center; Gastroenterology
-
Hadera, 이스라엘, 38100
- Hillel Yaffe Hospital; Gastroenterology
-
Haifa, 이스라엘, 31096
- Rambam Medical Center; Gastroenterology - Liver Unit
-
Haifa, 이스라엘, 33394
- Bnei-Zion Medical Center; Gastroenterology
-
Haifa, 이스라엘, 34362
- Carmel Hospital; Liver Unit
-
Holon, 이스라엘, 58100
- Wolfson Hospital; Gastroenterology Unit
-
Jerusalem, 이스라엘, 91031
- Shaare Zedek Hospital Liver Unit; Liver Unit
-
Jerusalem, 이스라엘, 91120
- Hadassah Hospital; Liver Unit
-
Kfar Saba, 이스라엘, 44281
- Meir Medical Center; Liver Unit
-
Nahariya, 이스라엘, 22100
- Western Galilee Hospital - Nahariya
-
Nazareth, 이스라엘
- Holy Family Medical Center; Liver Unit
-
Petach Tikva, 이스라엘
- Hasharon Mc; Gastroenterology
-
Petah Tiqwa, 이스라엘
- Beilinson-Rabin Liver Unit; Liver Unit
-
Ramat Gan, 이스라엘, 5262100
- Sheba Medical Center; Tel Hashomer
-
Rehovot, 이스라엘, 76100
- Kaplan Medical Center; Gastroenterology Unit
-
Safed, 이스라엘, 13110
- Rebecca Sieff Medical Center; Liver Unit
-
Tel Aviv, 이스라엘, 6423906
- Tel-Aviv Sourasky Medical Center; Liver Unit
-
Tiberias, 이스라엘
- Poria Hospital; Gastroenterology
-
Zerifin, 이스라엘, 6093000
- Assaf Harofeh; Gastroenterology
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Chronic hepatitis C (all genotypes, naïve or treatment experienced, HCV mono-infected or HCV-HIV co-infected)
- Receiving either dual therapy (Pegasys plus ribavirin) or triple therapy (Pegasys plus ribavirin plus telaprevir/boceprevir)
- No contra-indications to Pegasys and ribavirin therapy or to treatment regimen containing protease inhibitor (telaprevir or boceprevir) as detailed in local Prescribing Information
- Quantitative serum HCV RNA by PCR test before initiation of treatment
Exclusion Criteria:
- Hepatitis A/B co-infection
- Evidence of severe illness, active malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
- Pregnant or breast-feeding women
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: 보병대
- 시간 관점: 유망한
코호트 및 개입
그룹/코호트 |
---|
보병대
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of Participants With Sustained Viral Response (SVR) at Week 24
기간: Week 24
|
The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels < 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion.
|
Week 24
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Comparison of SVR at Week 24
기간: Week 24
|
SVR at Week 24 is compared by treatment group, type of infection, prior treatments and genotype.
|
Week 24
|
Number of Participants With SVR at Week 24 According to the Demographic Characteristics
기간: Week 24
|
The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels < 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion.
Number of participants analysed signifies participants who were evaluated for outcome measure.
Data for this outcome measure was not summarized for each arm.
Hence, data is reported for all participants.
|
Week 24
|
Percentage of Participants With Rapid Virologic Response (RVR) at Week 4
기간: Week 4
|
RVR was defined as HCV-RNA <50 IU/mL by Week 4
|
Week 4
|
Percentage of Participants With Extended RVR
기간: Week 4 and 12 for telaprevir group; Week 8 and 24 for boceprevir group
|
Extended RVR was defined as HCV-RNA <50 IU/mL at weeks 4 and 12 for participants treated with telaprevir; or at weeks 8 & 24 for participants treated with boceprevir. The assessment was performed in participants who received triple therapy in treatment arms 'Peginterferon Alfa-2a + Ribavirin +Telaprevir' and 'Peginterferon Alfa-2a + Ribavirin + Boceprevir'. |
Week 4 and 12 for telaprevir group; Week 8 and 24 for boceprevir group
|
Percentage of Participants With Complete Early Virologic Response (cEVR)
기간: Week 12
|
Complete early virologic response (cEVR) was defined as HCV-RNA <50 IU/mL by Week 12
|
Week 12
|
Percentage of Participants With End of Treatment Response (EoT)
기간: Week 24
|
End-of-Treatment (EoT) response was defined as HCV-RNA <50 IU/mL by the end of treatment.
|
Week 24
|
Percentage of Participants With Virologic Relapse
기간: Week 72
|
Virologic relapse was defined as detectable HCV-RNA during the treatment-free follow-up period in participants with HCV-RNA <50 IU/mL at EoT.
|
Week 72
|
Treatment Duration
기간: Week 48
|
The average amount of time a treatment was prescribed to participants.
|
Week 48
|
Time to First Dose Modification of Peginterferon Alfa-2a
기간: Week 48
|
Week 48
|
|
Time to First Dose Modification of Ribavirin
기간: Week 48
|
Week 48
|
|
Time to First Dose Modification of Telaprevir/Boceprevir
기간: Week 48
|
Week 48
|
|
Percentage of Participants With Adverse Events (AEs)
기간: Week 48
|
Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Safety analysis included 2 additional participants in arm 'Peginterferon Alfa-2a + Ribavirin + Telaprevir'. The safety parameters were analyzed by the treatment actually received by the participants. |
Week 48
|
Mean Value of Hemoglobin in Participants With Treatment-Induced Anemia
기간: Week 48
|
Week 48
|
|
Percentage of Participants With Treatment Regimen for HCV Treatment Induced Anemia
기간: Week 48
|
Week 48
|
|
Percentage of Participants Who Had SVR at Week 24 With Dose Modifications
기간: Week 24
|
Participants with dose modifications who had achieved SVR at Week 24 were reported.
Data was collected for all participants who had dose modification of Peginterferon alfa-2a, Ribavirin or Telaprevir/boceprevir in any of the treatment regimen during the study.
|
Week 24
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ML28268
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
만성 C형 간염에 대한 임상 시험
-
Hospital Clinic of BarcelonaAstraZeneca완전한CTO(Chronic Total Occlusion)를 위한 PCI(Percutaneous Coronary Intervention)를 받을 예정인 환자스페인
-
Meir Medical Center완전한디지털 스테레오 광 디스크 이미지에서 C/D 비율을 측정하는 새로운 기술 개발 | C/D 측정의 관찰자 내 재현성 | C/D 측정의 관찰자 간 가변성
-
University Hospital, GrenobleClinical Investigation Centre for Innovative Technology Network완전한
-
Haisco Pharmaceutical Group Co., Ltd.완전한
-
University Hospital, Caen완전한
-
University of Sao Paulo General HospitalInCor Heart Institute; Chinese Academy of Medical Sciences, Fuwai Hospital; Beneficência... 그리고 다른 협력자들알려지지 않은